Safety and efficacy of a basal-plus regimen with insulin glargine and insulin glulisine for elderly patients with high cardiovascular risk and type 2 diabetes mellitus

• Published in: Revista clínica espanõla (English edition) 2017-05, Vol.217 (4), p.201-206
• Main Authors: Gómez-Huelgas, R, Sabán-Ruiz, J, García-Román, F J, Quintela-Fernández, N, Seguí-Ripoll, J M, Bonilla-Hernández, M V, Romero-Meliá, G
• Format: Article
• Language: eng ; spa
• ISSN: 2254-8874
• DOI: 10.1016/j.rce.2017.02.005

OBJECTIVESTo assess the safety and efficacy of a basal-plus (BP) regimen with insulin glargine (as basal insulin) and insulin glulisine (as prandial insulin) with the main meal for elderly patients with type 2 diabetes mellitus (DM2) and high cardiovascular risk, following standard clinical practice. PATIENTS AND METHODSAn observational, retrospective study was conducted in 21 centres of internal medicine in Spain. The study included patients aged 65 years or older with DM2, undergoing treatment with a BP regimen for 4 to 12 months before inclusion in the study and a diagnosis of cardiovascular disease or high cardiovascular risk. The primary endpoint was the change in glycated haemoglobin (HbA1c) from the introduction of the glulisine to inclusion in the study. RESULTSThe study included 198 patients (mean age, 74±6.4 years; males, 52%). After at least 4 months of treatment with the BP regimen, started with the addition of glulisine, the mean HbA1c value decreased significantly (9±1.5% vs. 7.7±1.1%; P